Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1652 1671
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17775446 | BIPARATOPIC CD73 ANTIBODIES | Final Rejection | GENZYME CORPORATION |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18457729 | BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP | Final Rejection | Hoffmann-La Roche Inc. |
| 18238153 | CONTORSBODY - A SINGLE CHAIN TARGET BINDER | Final Rejection | Hoffmann-La Roche Inc. |
| 18030223 | ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17905043 | COMBINED ANTI-CYTOKINE THERAPY TO REDUCE METASTATIC CANCER | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | Non-Final OA | Bristol-Myers Squibb Company |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | Non-Final OA | Bristol-Myers Squibb Company |
| 18122194 | METHODS OF TREATING GLIOBLASTOMA | Final Rejection | Ramot at Tel-Aviv University Ltd. |
| 16479652 | MINI-CANCERS UTILIZATION FOR PERSONALIZED CANCER DRUG REGIMENS | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18256222 | Agent for Preventing or Treating Frontotemporal Lobar Degeneration | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18547644 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ALLOSTERIC PROTEINS | Non-Final OA | UNIVERSITY OF WASHINGTON |
| 18718387 | FULLY CANINE ANTI-CANINE PD-1 ANTIBODIES AND USES THEREOF | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17657537 | PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | Final Rejection | PRELUDE CORPORATION |
| 18247877 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 17918479 | TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18055406 | TUMOR-INTRINSIC NLRP3 INFLAMMASOME SIGNALING PATHWAY AS A GENETIC AND FUNCTIONAL BIOMARKER FOR IMMUNOTHERAPY RESPONSE | Non-Final OA | Duke University |
| 17926235 | TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | Non-Final OA | ASTRAZENECA AB |
| 17666999 | METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER | Non-Final OA | Memorial Hospital for Cancer and Allied Diseases |
| 18745729 | ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - |
| 18263860 | TARGETED PROTEIN DEGRADATION SYSTEM AND USE THEREOF | Non-Final OA | ST PHI THERAPEUTICS CO., LTD. |
| 18256556 | High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody | Non-Final OA | Albert Einstein College of Medicine |
| 17296506 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | Non-Final OA | DENALI THERAPEUTICS INC. |
| 18032101 | CORONA VIRUS-SPECIFIC T CELL RECEPTOR FUSION CONSTRUCTS, VECTORS ENCODING THE SAME, T CELLS COMPRISING THE SAME AND USES THEREOF | Non-Final OA | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG |
| 18587839 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | Non-Final OA | Xencor, Inc. |
| 17673686 | MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES | Non-Final OA | CEMM - Forschungszentrum für Molekulare Medizin GmbH |
| 17921543 | TREATMENT OF HER2 NEGATIVE, MAMMAPRINT HIGH RISK 2 BREAST CANCER | Final Rejection | Agendia N.V. |
| 18025208 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | GENMAB A/S |
| 18365369 | Method for Determining Prognosis of Cancer | Non-Final OA | Queen Mary University of London |
| 18355853 | METHOD FOR SCREENING A SUBJECT FOR CANCER | Non-Final OA | INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy